Cyclin D1、Ki-67、CK19联合评估甲状腺乳头状癌的效能及与颈部淋巴结转移的相关性分析

摘要/Abstract

摘要： 目的：探讨细胞周期蛋白D1（Cyclin D1）、细胞增殖抗原-67（Ki-67）、细胞角蛋白19（CK19）联合评估甲状腺乳头状癌（PTC）的效能，分析三者与颈部淋巴结转移的相关性。方法：选取我院2017年9月至2021年9月收治的91例PTC患者为PTC组，取同期收治的结节性甲状腺肿患者52例为对照组。两组均通过手术获取病变组织，检测Cyclin D1、Ki-67、CK19表达情况，分析三者对PTC的诊断价值。根据PTC患者有无颈部淋巴结转移，分成转移组、非转移组，比较两组病理组织中Cyclin D1、Ki-67、CK19表达情况，经多元Logistic回归模型分析三者与PTC患者颈部淋巴结转移的关系。结果： PTC组Cyclin D1、CK19阳性表达率分别为83.52%、85.71%，高于对照组的17.31%、17.31%（P＜0.05）；PTC组Ki-67＞1%占比为93.41%，高于对照组的13.46%（P＜0.05）。Cyclin D1、Ki-67、CK19单独诊断PTC的敏感度分别为83.52%、93.41%、85.71%，特异度分别为82.69%、86.54%、82.69%，三者联合诊断的敏感度、特异度分别为91.21%、96.15%。转移组的Cyclin D1、CK19阳性表达率分别为97.06%、97.06%，高于非转移组的75.44%、78.95%（P＜0.05）。多元Logistic回归分析显示，Cyclin D1阳性表达会增加PTC患者颈部淋巴结转移风险（OR：3.446，95%CI：1.041～11.407，P＜0.05）。结论： PTC患者的Cyclin D1、Ki-67、CK19阳性表达率较高，三者联合对PTC有较好的诊断效能，其中Cyclin D1阳性表达与颈部淋巴结转移相关。

关键词: font-size:medium, ">甲状腺乳头状癌；细胞周期蛋白D1；细胞增殖抗原-67；细胞角蛋白19；颈部淋巴结转移

Abstract: Objective： To investigate the efficacy of Cyclin D1， cell proliferation antigen Ki-67 and cytokeratin 19 (CK19) in the evaluation of papillary thyroid carcinoma (PTC)， and to analyze the correlation between Cyclin D1， Ki-67 and CK19 and cervical lymph node metastasis. Methods： 91 patients with PTC admitted to our hospital from September 2017 to September 2021 were selected as the PTC group， and 52 patients with nodular goiter admitted during the same period were selected as the control group. The pathological tissues of the two groups of patients were obtained by surgery， and the expressions of Cyclin D1， Ki-67 and CK19 were detected to analyze the diagnostic value of the three on PTC. The PTC patients were divided into metastatic group and non-metastatic group according to whether they had cervical lymph node metastasis. The expressions of Cyclin D1， Ki-67 and CK19 in pathological tissues of the two groups were compared， and the relationship between Cyclin D1， Ki-67， CK19 and cervical lymph node metastasis of PTC patients was analyzed by multiple Logistic regression model. Results： The positive expression rates of Cyclin D1 and CK19 in the PTC group were 83.52% and 85.71% respectively， which were higher than those of the control group (17.31% and 17.31%) （P＜0.05）.The proportion of Ki-67 > 1% in the PTC group was 93.41%， which was higher than that of the control group (13.46%) (P<0.05). The sensitivity of Cyclin D1， Ki-67 and CK19 in the diagnosis of PTC were 83.52%， 93.41% and 85.71% respectively， and the specificity of Cyclin D1， Ki-67 and CK19 were 82.69%， 86.54% and 82.69% respectively. The sensitivity and specificity of combined diagnosis were 91.21% and 96.15% respectively. The positive expression rates of Cyclin D1 and CK19 in metastatic group were 97.06% and 97.06% respectively， which were higher than those of the non-metastatic group （75.44% and 78.95%）（P<0.05）. Multiple Logistic regression analysis showed that positive Cyclin D1 expression increased the risk of cervical lymph node metastasis in PTC patients (OR： 3.446， 95%CI： 1.041-11.407， P<0.05). Conclusion： The positive expression rate of Cyclin D1， Ki-67 and CK19 in PTC patients is high， and the combination of these three factors has a good diagnostic efficacy for PTC.The positive expression of Cyclin D1 is related to cervical lymph node metastasis of PTC.

Key words: font-size:medium, ">Papillary thyroid carcinoma； Cyclin D1； Cell proliferation antigen Ki-67； Cytokeratin 19； Cervical lymph node metastasis

中图分类号:

徐子森, 阚炳华. Cyclin D1、Ki-67、CK19联合评估甲状腺乳头状癌的效能及与颈部淋巴结转移的相关性分析[J]. 中国医药导刊, 2023, 25(6): 596-600.

XU Zisen, KAN Binghua. Efficacy of Cyclin D1， Ki-67 and CK19 Combined Evaluation of Papillary Thyroid Carcinoma and Its Correlation with Cervical Lymph Node Metastasis[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(6): 596-600.

参考文献

[1]Wong KS， Dong F， Telatar M， et al. Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma： an analysis of clinicopathologic and molecular features and outcome[J]. Thyroid， 2021， 31(6)：933-940.
     [2]杜瑞，梁楠，孙辉.儿童及青少年甲状腺癌诊疗进展[J]. 中国普通外科杂志，2019，28(11)：1421-1426.
     [3]Liu D， Li P， Wang X， et al. hsa-miR-195-5p inhibits cell proliferation of human thyroid carcinoma cells via modulation of p21/cyclin D1 axis[J]. Transl Cancer Res， 2020， 9(9)：5190-5199.
     [4]张强，霍占江，田亮，等. 细胞角蛋白19通过调控MAPK和PTEN通路促进甲状腺癌细胞的增殖，侵袭及转移[J]. 医学分子生物学杂志， 2022， 19(5)：399-402.
     [5]程亮亮，刘哲，于显凤.MSCT联合CEA，Ki-67及CA125检测对卵巢癌的诊断价值[J]. 中国CT和MRI杂志，2021，19(3)：104-106.
     [6]唐军. 医学统计学[M]. 北京：人民军医出版社， 2003：87.
     [7]陈杰. 病理诊断免疫组化手册[M]. 北京：中国协和医科大学出版社， 2014：113.
     [8]Liu Z， Liu Y， Fan Y， et al. Level IIb lymph node metastasis characteristics and predictive factors for patients with cN1b papillary thyroid carcinoma[J]. Surgery， 2020， 167(6)：962-968.
     [9]滕卫平. 甲状腺疾病诊治现代进展[J]. 中国实用内科杂志，2019，39(4)：311-315.
     [10]Okabe N， Fujiwara M， Tachibana K， et al. STAT3 activation in thymic epithelial tumors： correlation with cyclin D1， JAK3， and clinical behavior[J]. Gen Thorac Cardiovasc Surg， 2021，69(11)：1482-1491.
     [11]韩志蓉，奉泽锦，韩亮.E-cadherin和CK19表达与甲状腺乳头状癌患者临床病理特征和复发的关系[J]. 现代肿瘤医学，2021，29(2)：220-224.
     [12]陈妮娜，范怡畅，尚昆，等. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报，2019，40(2)：191-194.
     [13]刘佳杰，徐猛，刘宝豪，等.环指蛋白180、p53及Ki-67在肾透明细胞癌中的表达及临床意义[J]. 中国临床药理学杂志，2021，37(18)：2405-2408.
     [14]侯卫东，李会敏，田勇，等.细胞周期蛋白D1标记指数在甲状腺乳头状癌中诊断临界值的探讨[J]. 中华内分泌代谢杂志，2020，36(12)：1045-1050.
     [15]王杰，向德兵，唐瑶，等.FBXO31与细胞周期蛋白D1在结直肠腺癌中的表达及临床意义[J]. 重庆医学，2019，48(3)：420-422，427.
     [16]Fuchs TL， Nassour AJ， Glover A， et al. A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (Ki-67 and mitotic count) and coagulative necrosis[J]. Am J Surg Pathol， 2020，44(10)：1419-1428.
     [17]何时知，房居高，陈佳铭，等. 分化型甲状腺癌中Cyclin D1， Galectin-3和ki-67的表达及其与侵袭的关系[J]. 河南师范大学学报(自然科学版)，2020，48(2)：113-117.
     [18]Mehrpouya M， Pourhashem Z， Yardehnavi N， et al. Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods[J]. J Cell Physiol， 2019，234(12)：21425-21435.
     [19]冯凌飞，贺曾，王景玉. 甲状腺癌组织中CK19，ARID1 A表达水平及与其临床病理参数及预后的关系[J]. 实用癌症杂志， 2021， 36(6)：947-950.
     [20]魏广民，周文波，武伦，等. CyclinD1和Bax在甲状腺微小乳头状癌中的表达及意义[J]. 重庆医学，2017，46(3)：325-328.

快速检索引用检索图表检索高级检索